美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

艾格里房产

75.31

+0.80501.08%

成交量：50.50万

成交额：3,769.55万

市值：82.69亿

市盈率：42.58

高：75.31

开：74.59

低：74.21

收：74.50

数据加载中...

总览公司新闻公告

【新股IPO】据报宜联生物寻求ADC药物YL201授权合作为公司最快2026年在港上市铺路

新股消息 | 传宜联生物考虑最快明年在港上市

Nuvation Bio Inc.盘中异动股价大涨5.32%报1.98美元

药明合联与AbTis宣布达成战略合作，共同推进新一代ADC药物研发

辉瑞(PFE)PD-L1靶向ADC新药在华获批临床

辉瑞(PFE.US)PD-L1靶向ADC新药在华获批临床拟治疗晚期实体瘤

基石药业-B(02616)：迈向管线2.0，ROR1 ADC潜力十足

智通财经网

Nuvation Bio Inc.盘中异动股价大跌10.84%

美国研究综述-芝商所、Docusign、Paycom Software

科伦博泰生物核心产品获批新增适应症

映恩生物二战港交所：尚无商业化产品累亏超17亿元强力竞品已纳入医保降价超60%

第一三共(DSNKY.US)ADC癌症新药在中国获批临床

【基石药业-B(02616.HK)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请】基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。

基石药业-B(02616)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请

第一三共/阿斯利康(AZN.US)重磅抗体偶联药物(ADC)Enhertu在3期临床试验中获得积极结果

石药预付款助力康宁杰瑞首次盈利，ADC管线成股价催涨剂丨看财报

Nuvation Bio Inc.盘中异动早盘股价大跌5.22%报1.73美元

巴克莱：上调Agree Realty(ADC.US)评级，由减持调整至持股观望评级, 目标价由74.00美元调整至75.00美元。

丽珠集团：已终止HER2-ADC项目后续推进，聚焦优势项目研发进展

一款重磅ADC药物上市申请延迟乐普生物股价大跌逾10%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ADC/news?page=6"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":75.305,"timestamp":1748029523693,"preClose":74.5,"halted":0,"volume":504977,"delay":0,"floatShares":107727624,"shares":109806548,"eps":1.768583,"marketStatus":"交易中","change":0.805,"latestTime":"05-23 15:45:24 EDT","open":74.585,"high":75.31,"low":74.21,"amount":37695482.69784,"amplitude":0.014765,"askPrice":75.3,"askSize":20,"bidPrice":75.27,"bidSize":107,"shortable":3,"etf":0,"ttmEps":1.768583,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1748030400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":74.5,"dividendRate":0.040077,"preHourTrading":{"tag":"盘前","latestPrice":74.31,"preClose":74.5,"latestTime":"09:25 EDT","volume":44,"amount":3276.04464,"timestamp":1748006705583},"postHourTrading":{"tag":"盘后","latestPrice":74.5,"preClose":74.5,"latestTime":"17:51 EDT","volume":18559,"amount":1382642.91,"timestamp":1747950711510},"volumeRatio":0.524013,"impliedVol":0.2184,"impliedVolPercentile":0.552},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","floatShares":107727624,"roa":"2.30%","roe":"3.55%","lyrEps":1.793039,"volumeRatio":0.524013,"shares":109806548,"dividePrice":3.018,"high":75.31,"amplitude":0.014765,"preClose":74.5,"low":74.21,"week52Low":58.52,"pbRate":"1.51","psRate":"12.99","week52High":79.65,"institutionHeld":0.8991,"latestPrice":75.305,"committee":0.685039,"eps":1.768583,"divideRate":0.040077,"volume":504977,"delay":0,"ttmEps":1.768583,"open":74.585,"prevYearClose":70.45,"prevWeekClose":74.92,"prevMonthClose":77.61,"prevQuarterClose":77.19,"fiveDayClose":74.92,"twentyDayClose":75.67,"sixtyDayClose":73.69},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518058979","title":"【新股IPO】据报宜联生物寻求ADC药物YL201授权合作 为公司最快2026年在港上市铺路","url":"https://stock-news.laohu8.com/highlight/detail?id=2518058979","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518058979?lang=zh_cn&edition=fundamental","pubTime":"2025-03-12 14:54","pubTimestamp":1741762478,"startTime":"0","endTime":"0","summary":"金吾财讯 | 有报道引述中国宜联生物公司(MediLink Therapeutics　Ltd)正寻求就旗下抗体偶联药物(ADC)YL201，与一家全球制药公司达成授权协议，这将为公司最快2026年在香港上市铺路。消息指，目前的协商仍在进行当中，最终是否能够达成协议还无法确定。据悉，宜联生物总部位于苏州，于2020年7月8日成立，是一家专注于ADC（抗体偶联药物）及相关技术创新药物开发的企业，并且在上海和波士顿设置了研发中心。YL201是一款靶向B7H3的ADC药物。目前，YL201正在全球范围内开展针对多种实体瘤的探索性研究。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/MWIxNzM2MjE4MjI2OTA1.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MWIxNzM2MjE4MjI2OTA1.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1954895","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4231","ADC"],"gpt_icon":0},{"id":"2518854058","title":"新股消息 | 传宜联生物考虑最快明年在港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2518854058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518854058?lang=zh_cn&edition=fundamental","pubTime":"2025-03-12 14:48","pubTimestamp":1741762116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据媒体消息称，宜联生物正寻求就旗下抗体偶联药物(ADC)YL201，与一家全球制药公司达成授权协议，这将为公司最快2026年在香港上市铺路。消息指，蹉商仍在进行中，未必可以达成协议。据了解，宜联生物是一家专注于ADC和相关技术的创新药物开发公司。公司在上海和波士顿设有研发中心。YL201是一款靶向B7H3的ADC药物。目前，YL201正在全球范围内开展针对多种实体瘤的探索性研究。其中，小细胞肺癌、鼻咽癌适应症在中国已进入关键临床III期研究阶段。同时，YL201也在积极开展多种联用试验，探索其在多种实体瘤的前线治疗潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK4080","BK4231"],"gpt_icon":0},{"id":"2518721237","title":"Nuvation Bio Inc.盘中异动 股价大涨5.32%报1.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518721237","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518721237?lang=zh_cn&edition=fundamental","pubTime":"2025-03-12 00:22","pubTimestamp":1741710121,"startTime":"0","endTime":"0","summary":"北京时间2025年03月12日00时22分，Nuvation Bio Inc.股票出现波动，股价大幅上涨5.32%。截至发稿，该股报1.98美元/股，成交量136.184万股，换手率0.40%，振幅7.98%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为2.37%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250312002201ab5e2706&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250312002201ab5e2706&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4212","BK4007","DDC","ADC","NUVB","BK4080","BK4231"],"gpt_icon":0},{"id":"2518472887","title":"药明合联与AbTis宣布达成战略合作，共同推进新一代ADC药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2518472887","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518472887?lang=zh_cn&edition=fundamental","pubTime":"2025-03-11 21:17","pubTimestamp":1741699020,"startTime":"0","endTime":"0","summary":"药明合联将依托其广泛的全球客户网络，全力推动AbTis技术的广泛应用，助力双方在生物偶联药领域的深度合作与共赢。此次合作将AbTis的先进ADC技术与药明合联的专业开发及生产能力深度融合，将为我们的客户提供更广泛先进的生物偶联技术选择和定制化解决方案，加速新一代 ADC 和生物偶联药物的研发进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4638419_ZH38419_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1141","SG9999014674.SGD","LU2488822045.USD","BK4231","02268","ADC","BK4080"],"gpt_icon":0},{"id":"2518797147","title":"辉瑞(PFE)PD-L1靶向ADC新药在华获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2518797147","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518797147?lang=zh_cn&edition=fundamental","pubTime":"2025-03-11 17:07","pubTimestamp":1741684053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国国家药监局药品审评中心 3月10日公示，辉瑞与Seagen联合开发的1类新药PF-08046054获得临床试验默示许可，拟开展转移性或不可切除晚期实体瘤适应症研究。该药物是辉瑞研发管线中首款靶向PD-L1的抗体偶联药物，具有\"first-in-class\"潜力。PF-08046054采用独特的抗PD-L1抗体-药物偶联设计，由抗PD-L1单抗、可裂解连接子及微管抑制剂MMAE组成。相较于传统PD-1/PD-L1抑制剂，该药物通过结合ADC的双重作用机制，可能为PD-L1表达不足或耐药的实体瘤患者提供新治疗选择。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"286261","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU1883839398.USD","LU0985481810.HKD","LU1169589451.USD","SG9999002232.USD","SG9999002224.SGD","BK4007","BK4534","BK4581","IE00BBT3K403.USD","LU1023059063.AUD","LU1057294990.SGD","LU1894683264.USD","SG9999013999.USD","SG9999001176.SGD","SGXZ57979304.SGD","BK4080","BK4550","BK4592","LU0306806265.USD","LU1066053197.SGD","LU0225771236.USD","IE000M9KFDE8.USD","BK4585","IE00B19Z3581.USD","LU0321505439.SGD","BK4588","LU0289739699.SGD","SG9999001176.USD","PFE","LU1066051498.USD","ADC","LU0868494617.USD","LU0456855351.SGD","LU0321505868.SGD","LU1894683348.USD","BK4023","LU0170899867.USD","LU0306807586.USD","BK4533","IE00BLSP4239.USD","LU0122379950.USD","LU0058720904.USD","LU0225284248.USD","SG9999003800.SGD","IE00B19Z3B42.SGD","LU1169590202.USD","PD","BK4231","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2518980763","title":"辉瑞(PFE.US)PD-L1靶向ADC新药在华获批临床 拟治疗晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2518980763","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518980763?lang=zh_cn&edition=fundamental","pubTime":"2025-03-11 14:10","pubTimestamp":1741673430,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月10日，中国国家药监局药品审评中心官网最新公示，辉瑞公司旗下Seagen申报的1类新药PF-08046054获得临床试验默示许可，拟开发治疗转移性或不可切除的晚期实体瘤。公开资料显示，这是辉瑞在研的一款潜在“first-in-class”PD-L1靶向抗体偶联药物。截图来源：CDE官网根据辉瑞公开资料介绍，PF-08046054是一款靶向PD-L1的ADC，由抗PD-L1抗体、连接子和微管破坏剂MMAE组成，可通过直接细胞毒性、旁观者杀伤、免疫原性细胞死亡来发挥抗肿瘤活性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999001176.SGD","LU0985481810.HKD","BK4588","LU1169589451.USD","BK4592","BK4533","IE00B19Z3581.USD","LU1057294990.SGD","SG9999001176.USD","LU1169590202.USD","SG9999002232.USD","LU0122379950.USD","LU1066051498.USD","LU0306806265.USD","LU0321505439.SGD","SG9999011175.SGD","IE00BLSP4452.SGD","LU0225771236.USD","LU1066053197.SGD","BK4534","LU0289739699.SGD","BK4007","IE00BBT3K403.USD","LU0058720904.USD","LU0170899867.USD","LU0225284248.USD","PD","BK4585","SG9999002224.SGD","LU1883839398.USD","PFE","LU0234572021.USD","LU1023059063.AUD","SG9999003800.SGD","LU1894683348.USD","BK4023","BK4080","LU0868494617.USD","LU1894683264.USD","BK4599","BK4581","BK4231","LU0321505868.SGD","SGXZ57979304.SGD","BK4550","SG9999013999.USD","LU0306807586.USD","IE0002270589.USD","IE00B19Z3B42.SGD","ADC"],"gpt_icon":1},{"id":"2518732608","title":"基石药业-B(02616)：迈向管线2.0，ROR1 ADC潜力十足","url":"https://stock-news.laohu8.com/highlight/detail?id=2518732608","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518732608?lang=zh_cn&edition=fundamental","pubTime":"2025-03-11 09:59","pubTimestamp":1741658376,"startTime":"0","endTime":"0","summary":"基石药业是一家专注于抗肿瘤药物研发的创新驱动型生物医药企业，截至2025年2月，公司已成功上市4款创新药、获批16项新药上市申请（NDA以及9项适应症。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20250311/20250311100302_75957.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250311/20250311100302_75957.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4080","BK1161","ADC","02616","BK1574","BK4231"],"gpt_icon":0},{"id":"2518303271","title":"Nuvation Bio Inc.盘中异动 股价大跌10.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518303271","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518303271?lang=zh_cn&edition=fundamental","pubTime":"2025-03-10 21:33","pubTimestamp":1741613585,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时33分，Nuvation Bio Inc.股票出现波动，股价急速下跌10.84%。截至发稿，该股报1.80美元/股，成交量4.4904万股，换手率0.01%，振幅3.17%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为0.08%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213305abf2fcdb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213305abf2fcdb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DDC","BK4231","BK4007","BK4080","ADC","BK4212","NUVB"],"gpt_icon":0},{"id":"2518226661","title":"美国研究综述-芝商所、Docusign、Paycom Software","url":"https://stock-news.laohu8.com/highlight/detail?id=2518226661","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518226661?lang=zh_cn&edition=fundamental","pubTime":"2025-03-10 20:49","pubTimestamp":1741610952,"startTime":"0","endTime":"0","summary":"美国研究综述-芝商所、Docusign、Paycom Software路透3月10日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 芝商所、Docusign 和 Paycom Software。* Docusign Inc DOCU.O：摩根大通将其评级从 \"减持 \"上调至 \"中性\"。* Paycom Software, Inc：Keybanc将其评级从行业权重上调至增持 * Samsara Inc IOT.N：Piper Sandler 将评级从中性上调至增持以下是路透周一报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL4T3PT0YS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASB","LU2430703095.HKD","AESI","ABNB","ADC","AMT","CPT","DVN","LU1989764664.SGD","LU0742537680.HKD","CDXC","APEI","CYH","ASTH","CHPT","CME","EQR","CDTX","DXPE","CTRE","XYZ","LU1934455277.USD","GTLS","AARD","LU1718418525.SGD","LU0472753341.HKD","BKSY","ALTG","LU0128525689.USD","ESS","APA","LU0444973449.USD","EQIX","DLR","COLD","EPR","DOCU","AVB","BK4595","BK4542","EPRT","LU1244550577.SGD","BLMN","AEP","ELME","CBRL","DD"],"gpt_icon":1},{"id":"2518319245","title":"科伦博泰生物核心产品获批新增适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2518319245","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518319245?lang=zh_cn&edition=fundamental","pubTime":"2025-03-10 17:55","pubTimestamp":1741600521,"startTime":"0","endTime":"0","summary":"3月10日，科伦博泰生物-B（06990）发布公告，公司的核心产品芦康沙妥珠单抗（sac-TMT）近日获得国家药品监督管理局批准，新增适应症用于EGFR突变非小细胞肺癌的治疗。这一批准使得芦康沙妥珠单抗成为全球首个在肺癌适应症获批上市的TROP2抗体药物偶联物（ADC），标志着公司在抗癌药物领域的重要进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503103341366183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU0196878994.USD","ADC","06990","BK4231","BK4080"],"gpt_icon":0},{"id":"2517610941","title":"映恩生物二战港交所：尚无商业化产品累亏超17亿元 强力竞品已纳入医保降价超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517610941","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517610941?lang=zh_cn&edition=fundamental","pubTime":"2025-03-07 17:10","pubTimestamp":1741338600,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　2月27日，映恩生物向港交所提交上市申请，拟通过上市规则18A寻求在联交所主板上市，摩根士丹利、杰弗瑞、中信证券为其联席保荐人。这是继其于2024年8月26日递表失效后的再一次申请。截至2024年9月末，公司累亏超17亿元。招股书显示，2022年5月26日，映恩生物与药明生物间接全资附属公司WuXi Biologics订立许可协议，获得了B7-H3抗体。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-03-07/doc-inenvmwf5759065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4118","BK4566","BK4588","BK4231","DB","BK4080","ADC","BK4552"],"gpt_icon":0},{"id":"2517815279","title":"第一三共(DSNKY.US)ADC癌症新药在中国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2517815279","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517815279?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 21:20","pubTimestamp":1741267210,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月6日，中国国家药监局药品审评中心官网公示，第一三共申报的1类新药DS-3939a获批临床，拟开发治疗实体瘤。公开资料显示，DS-3939a是一种靶向肿瘤相关MUC1的抗体偶联药物，正在全球范围内处于1/2期临床研究阶段。根据CDE官网查询，本次为该产品首次在中国获批临床。本次这款创新ADC在中国获批临床，意味着其将在中国进入临床研究阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","DSNKY","BK4007","ADC","BK4231"],"gpt_icon":0},{"id":"2517497936","title":"【基石药业-B(02616.HK)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请】基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517497936","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517497936?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 08:13","pubTimestamp":1741220034,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06081348552983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4231","PD","BK1583","LU1169589451.USD","LU1169590202.USD","ADC","BK4023","BK1574","BK1141","BK1161","02616","03347","BK1576","BK4080"],"gpt_icon":0},{"id":"2517763909","title":"基石药业-B(02616)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2517763909","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517763909?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 08:07","pubTimestamp":1741219667,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司已在澳大利亚成功递交CS5001联合标准治疗用于一线弥漫大B细胞淋巴瘤的Ib期临床试验申请。CS5001用于治疗多种实体瘤的全球多中心Ib期临床试验正在同步开展中。本次Ib期临床试验在CS5001单药治疗后线侵袭性和惰性晚期淋巴瘤的数据基础上进一步拓展，旨在深入探索ROR1 ADC在DLBCL全病程的临床应用价值，并持续拓展实体瘤治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4080","ADC","02616","BK1574","BK1583","03347","BK1576","BK4231","BK1141"],"gpt_icon":0},{"id":"2517111989","title":"第一三共/阿斯利康(AZN.US)重磅抗体偶联药物(ADC)Enhertu在3期临床试验中获得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2517111989","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517111989?lang=zh_cn&edition=fundamental","pubTime":"2025-03-05 21:15","pubTimestamp":1741180517,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿斯利康和第一三共公司日前宣布，双方联合开发的重磅抗体偶联药物Enhertu，在3期临床试验DESTINY-Gastric04中获得积极结果。新闻稿表示，Enhertu是首个在随机3期临床试验中，作为二线疗法显著改善HER2阳性胃癌患者总生存期的HER2靶向疗法。新闻稿指出，转移性HER2阳性胃癌一线治疗出现疾病进展后，历史上在随机临床试验中，尚未有HER2靶向药物在二线治疗中展示出生存获益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZN","03347","LU1829250122.USD","LU2417539215.USD","BK1583","BK4231","BK1141","LU0889565916.HKD","ADC","BK4585","LU2456880835.USD","LU2236285917.USD","BK4568","LU0320765992.SGD","BK4080","BK1576","LU2462157665.USD","BK4007","LU0109394709.USD","BK4588"],"gpt_icon":1},{"id":"2517916826","title":"石药预付款助力康宁杰瑞首次盈利，ADC管线成股价催涨剂丨看财报","url":"https://stock-news.laohu8.com/highlight/detail?id=2517916826","media":"钛媒体","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517916826?lang=zh_cn&edition=fundamental","pubTime":"2025-03-05 20:24","pubTimestamp":1741177494,"startTime":"0","endTime":"0","summary":"3月5日，康宁杰瑞高开高走，收涨15.46%，最新总市值58.20亿港元。在这项合作中，康宁杰瑞有权收取高达6.16亿美元的一次性预付款及潜在里程碑付款，并可就各ADC产品向ArriVent收取分级销售特许权使用费。换句话说，石药集团的大额预付款不仅填平了公司日常经营产生的亏损窟窿，还将康宁杰瑞推向了盈利。值得注意的是，这并非石药集团首次与康宁杰瑞达成合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/05202448546520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["GLW","ADC","01093"],"gpt_icon":0},{"id":"2516767075","title":"Nuvation Bio Inc.盘中异动 早盘股价大跌5.22%报1.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516767075","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516767075?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 22:53","pubTimestamp":1741099989,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时53分，Nuvation Bio Inc.股票出现波动，股价快速跳水5.22%。截至发稿，该股报1.73美元/股，成交量22.0705万股，换手率0.07%，振幅2.75%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.32%。Nuvation Bio Inc.公司简介：Nuvation Bio Inc 是一家生物制药公司，致力于通过开发差异化的新型治疗候选药物来解决肿瘤学领域未满足的需求。值得注意的是，BET 蛋白具有重要的生物学功能，并且被发现在许多人类癌症中发生了改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304225310989bb29d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304225310989bb29d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DDC","BK4080","BK4212","BK4231","ADC","BK4007","NUVB"],"gpt_icon":0},{"id":"2516622313","title":"巴克莱：上调Agree Realty(ADC.US)评级，由减持调整至持股观望评级, 目标价由74.00美元调整至75.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516622313","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516622313?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 19:12","pubTimestamp":1741086762,"startTime":"0","endTime":"0","summary":"巴克莱：上调Agree Realty(ADC.US)评级，由减持调整至持股观望评级, 目标价由74.00美元调整至75.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04191248517971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ADC"],"gpt_icon":0},{"id":"2516762936","title":"丽珠集团：已终止HER2-ADC项目后续推进，聚焦优势项目研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2516762936","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516762936?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 18:09","pubTimestamp":1741082976,"startTime":"0","endTime":"0","summary":"金融界3月4日消息，有投资者在互动平台向丽珠集团提问：贵司与烟台迈百瑞，2016年达成协议共同开发ADC药物。还有在继续开发ADC药物吗？有无实质进展？公司回答表示：基于HER2-ADC项目的市场前景和竞争格局的综合考量，公司已终止该项目后续推进。目前公司生物药平台已建立抗体类药物、重组蛋白药物、重组蛋白疫苗等特色技术平台，未来将合理配置资源，进一步聚焦优势项目的研发进展。\n\n\r\n            责任编辑：安东","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04180948515547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK0028","BK0239","BK4080","ADC","BK4231","BK0187","000513"],"gpt_icon":0},{"id":"2516690588","title":"一款重磅ADC药物上市申请延迟 乐普生物股价大跌逾10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516690588","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516690588?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 10:35","pubTimestamp":1741055751,"startTime":"0","endTime":"0","summary":"【一款重磅ADC药物上市申请延迟 乐普生物股价大跌逾10%】2025年3月3日，国家药监局网站公布当日药品通知件送达信息，乐普生物（02157.HK）的维贝柯妥塔单抗（MRG003）名列其中。这意味着，该款药物的上市申请暂未成功获批。公司于3月4日早间回应称，为补充提交相关资料，公司主动撤回前次MRG003的NDA（新药上市申请）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503043335794853.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043335794853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02157","ADC","BK1161","BK4231","BK4080"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC\",params:#limit:5,,,undefined,":[{"date":"2025-05-30","symbol":"ADC","amount":0.256,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-30","defaultRemindTime":1748611800000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-13","payableDate":"2025-05-30","currency":"USD","dateTimestamp":1748577600000,"payDate":"2025-06-13"},{"date":"2025-04-30","symbol":"ADC","amount":0.256,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-30","defaultRemindTime":1746019800000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-14","payableDate":"2025-04-30","currency":"USD","dateTimestamp":1745985600000,"payDate":"2025-05-14"},{"market":"US","date":"2025-04-22","symbol":"ADC","fiscalQuarterEnding":"2025/03","expectedEps":1.05,"name":null,"time":"盘后","type":"earning","dateTimestamp":1745294400000,"reportTimeType":"post","actualEps":1.06},{"date":"2025-03-31","symbol":"ADC","amount":0.253,"announcedDate":"2025-03-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743427800000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-14","payableDate":"2025-03-31","currency":"USD","dateTimestamp":1743393600000,"payDate":"2025-04-14"},{"date":"2025-02-28","symbol":"ADC","amount":0.253,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-28","defaultRemindTime":1740753000000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-14","payableDate":"2025-02-28","currency":"USD","dateTimestamp":1740718800000,"payDate":"2025-03-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-26","recordDate":"2015-06-30","paymentDate":"2015-07-14","value":0.465,"currency":"USD"},{"executeDate":"2015-09-28","recordDate":"2015-09-30","paymentDate":"2015-10-13","value":0.465,"currency":"USD"},{"executeDate":"2015-12-18","recordDate":"2015-12-22","paymentDate":"2016-01-05","value":0.465,"currency":"USD"},{"executeDate":"2016-03-29","recordDate":"2016-03-31","paymentDate":"2016-04-15","value":0.465,"currency":"USD"},{"executeDate":"2016-06-28","recordDate":"2016-06-30","paymentDate":"2016-07-15","value":0.48,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.4286,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4286,"analysts":21,"updateTime":1746676800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ADC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ADC","date":"2025-05-22","current":43.002313,"percent":0.679414,"low":31.539495,"twenty":37.571542,"median":40.653059,"eighty":44.677947,"high":53.261716,"avg":41.113443,"sd":4.473729,"marketCap":8227804641},"quantilePoints":[{"date":"2020-05-29","current":40.87144,"twenty":30.127131,"median":35.446997,"eighty":42.650816,"marketCap":3390817259},{"date":"2020-06-05","current":44.67404,"twenty":30.209273,"median":35.585113,"eighty":42.788104,"marketCap":3706292371},{"date":"2020-06-12","current":43.306667,"twenty":30.259415,"median":35.631973,"eighty":42.882133,"marketCap":3592850978},{"date":"2020-06-19","current":43.938263,"twenty":30.399208,"median":35.674606,"eighty":42.926676,"marketCap":3645250098},{"date":"2020-06-26","current":40.969109,"twenty":30.470777,"median":35.744304,"eighty":42.989446,"marketCap":3398920216},{"date":"2020-07-02","current":43.619209,"twenty":30.497525,"median":35.833506,"eighty":43.024146,"marketCap":3618780439},{"date":"2020-07-10","current":41.587683,"twenty":30.543737,"median":35.93098,"eighty":43.037844,"marketCap":3450238941},{"date":"2020-07-17","current":42.77274,"twenty":30.603622,"median":36.099734,"eighty":43.037844,"marketCap":3548554815},{"date":"2020-07-24","current":37.537078,"twenty":30.71291,"median":36.149452,"eighty":43.037844,"marketCap":3365424257},{"date":"2020-07-31","current":40.350852,"twenty":30.745133,"median":36.199495,"eighty":43.037844,"marketCap":3617696027},{"date":"2020-08-07","current":41.351038,"twenty":30.776927,"median":36.250246,"eighty":43.037844,"marketCap":3707368648},{"date":"2020-08-14","current":40.224323,"twenty":30.922362,"median":36.348523,"eighty":43.037844,"marketCap":3606351900},{"date":"2020-08-21","current":40.308676,"twenty":31.08368,"median":36.544296,"eighty":43.037844,"marketCap":3613914651},{"date":"2020-08-28","current":40.628012,"twenty":31.203975,"median":36.640352,"eighty":43.037844,"marketCap":3642545066},{"date":"2020-09-04","current":40.013441,"twenty":31.296906,"median":36.781594,"eighty":43.037844,"marketCap":3587445022},{"date":"2020-09-11","current":40.079718,"twenty":31.383772,"median":36.974643,"eighty":43.037844,"marketCap":3593387184},{"date":"2020-09-18","current":38.59149,"twenty":31.509762,"median":37.052903,"eighty":43.037844,"marketCap":3459958646},{"date":"2020-09-25","current":37.645532,"twenty":31.534039,"median":37.273263,"eighty":43.037844,"marketCap":3375147794},{"date":"2020-10-02","current":39.29644,"twenty":31.704694,"median":37.362034,"eighty":43.037844,"marketCap":3523161638},{"date":"2020-10-09","current":40.368928,"twenty":31.803276,"median":37.497873,"eighty":43.037844,"marketCap":3619316617},{"date":"2020-10-16","current":39.386818,"twenty":31.867808,"median":37.57347,"eighty":43.037844,"marketCap":3531264585},{"date":"2020-10-23","current":40.224079,"twenty":31.975443,"median":37.612137,"eighty":43.037844,"marketCap":3633239960},{"date":"2020-10-30","current":38.164301,"twenty":31.975443,"median":37.733323,"eighty":43.037844,"marketCap":3447190528},{"date":"2020-11-06","current":38.797606,"twenty":31.975443,"median":37.935059,"eighty":43.037844,"marketCap":3504393786},{"date":"2020-11-13","current":41.26934,"twenty":31.975443,"median":38.046028,"eighty":43.037844,"marketCap":3727653105},{"date":"2020-11-20","current":40.039622,"twenty":31.975443,"median":38.167733,"eighty":43.037844,"marketCap":3616578817},{"date":"2020-11-27","current":40.506914,"twenty":31.975443,"median":38.310136,"eighty":43.037844,"marketCap":3658787046},{"date":"2020-12-04","current":40.580698,"twenty":31.975443,"median":38.471704,"eighty":43.037844,"marketCap":3665451504},{"date":"2020-12-11","current":40.230228,"twenty":31.975443,"median":38.545534,"eighty":43.037844,"marketCap":3633795331},{"date":"2020-12-18","current":39.344831,"twenty":31.975443,"median":38.676992,"eighty":43.037844,"marketCap":3553821844},{"date":"2020-12-24","current":39.762935,"twenty":31.975443,"median":38.782235,"eighty":43.037844,"marketCap":3591587102},{"date":"2020-12-31","current":40.937316,"twenty":31.975443,"median":38.892751,"eighty":43.037844,"marketCap":3697663047},{"date":"2021-01-08","current":45.450661,"twenty":31.975443,"median":39.008592,"eighty":43.047885,"marketCap":4105330986},{"date":"2021-01-15","current":44.653159,"twenty":31.975443,"median":39.245492,"eighty":43.22631,"marketCap":4033296550},{"date":"2021-01-22","current":45.359718,"twenty":31.975443,"median":39.341757,"eighty":43.313411,"marketCap":4097116533},{"date":"2021-01-29","current":44.212433,"twenty":31.975443,"median":39.41667,"eighty":43.4163,"marketCap":3993488046},{"date":"2021-02-05","current":46.262155,"twenty":31.975443,"median":39.41667,"eighty":43.554978,"marketCap":4178629185},{"date":"2021-02-12","current":45.520618,"twenty":31.975443,"median":39.41667,"eighty":43.618647,"marketCap":4111649797},{"date":"2021-02-19","current":43.859591,"twenty":31.975443,"median":39.41667,"eighty":43.642628,"marketCap":4007933303},{"date":"2021-02-26","current":44.718497,"twenty":31.977009,"median":39.430911,"eighty":43.756513,"marketCap":4086420942},{"date":"2021-03-05","current":44.656157,"twenty":31.975443,"median":39.41667,"eighty":43.796506,"marketCap":4080724259},{"date":"2021-03-12","current":46.594043,"twenty":31.975443,"median":39.41667,"eighty":43.856021,"marketCap":4257810284},{"date":"2021-03-19","current":46.240217,"twenty":31.975443,"median":39.41667,"eighty":43.889974,"marketCap":4225477299},{"date":"2021-03-26","current":46.69811,"twenty":31.977009,"median":39.430911,"eighty":43.995818,"marketCap":4267319985},{"date":"2021-04-01","current":47.239256,"twenty":31.977009,"median":39.430911,"eighty":44.083322,"marketCap":4316770432},{"date":"2021-04-09","current":47.1005,"twenty":31.975443,"median":39.41667,"eighty":44.146464,"marketCap":4304090831},{"date":"2021-04-16","current":47.627771,"twenty":31.975443,"median":39.41667,"eighty":44.201737,"marketCap":4352273317},{"date":"2021-04-23","current":49.334461,"twenty":31.975443,"median":39.41667,"eighty":44.216631,"marketCap":4508232419},{"date":"2021-04-30","current":48.814129,"twenty":31.975443,"median":39.41667,"eighty":44.274005,"marketCap":4460683913},{"date":"2021-05-07","current":44.881383,"twenty":31.975443,"median":39.41667,"eighty":44.314742,"marketCap":4499986938},{"date":"2021-05-14","current":44.377456,"twenty":31.975443,"median":39.41667,"eighty":44.249425,"marketCap":4449461218},{"date":"2021-05-21","current":44.026621,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4414285084},{"date":"2021-05-28","current":44.830352,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4494870410},{"date":"2021-06-04","current":45.665977,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4578653566},{"date":"2021-06-11","current":45.646841,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4576734868},{"date":"2021-06-18","current":47.246871,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4737160278},{"date":"2021-06-25","current":48.748389,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4887708512},{"date":"2021-07-02","current":48.211648,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4833892628},{"date":"2021-07-09","current":49.210395,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4934031046},{"date":"2021-07-16","current":49.93058,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5006239701},{"date":"2021-07-23","current":50.956505,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5109102975},{"date":"2021-07-30","current":53.056971,"twenty":31.977009,"median":39.430911,"eighty":44.230599,"marketCap":5165308396},{"date":"2021-08-06","current":52.598062,"twenty":31.977009,"median":39.430911,"eighty":44.296692,"marketCap":5120631744},{"date":"2021-08-13","current":52.520401,"twenty":31.977009,"median":39.430911,"eighty":44.412506,"marketCap":5113071079},{"date":"2021-08-20","current":52.718085,"twenty":31.977009,"median":39.430911,"eighty":44.625208,"marketCap":5132316407},{"date":"2021-08-27","current":52.209754,"twenty":31.977009,"median":39.430911,"eighty":44.658936,"marketCap":5082828422},{"date":"2021-09-03","current":52.675724,"twenty":31.977009,"median":39.430911,"eighty":44.712504,"marketCap":5128192408},{"date":"2021-09-10","current":49.555141,"twenty":31.977009,"median":39.430911,"eighty":44.74795,"marketCap":4824391169},{"date":"2021-09-17","current":50.119952,"twenty":31.977009,"median":39.430911,"eighty":44.835833,"marketCap":4879377818},{"date":"2021-09-24","current":47.775985,"twenty":31.977009,"median":39.430911,"eighty":44.888065,"marketCap":4651183223},{"date":"2021-10-01","current":47.352376,"twenty":31.977009,"median":39.430911,"eighty":44.941549,"marketCap":4609943235},{"date":"2021-10-08","current":47.670083,"twenty":31.977009,"median":39.430911,"eighty":44.9864,"marketCap":4640873226},{"date":"2021-10-15","current":49.02563,"twenty":31.977009,"median":39.430911,"eighty":45.094688,"marketCap":4772841185},{"date":"2021-10-22","current":49.5269,"twenty":31.977009,"median":39.430911,"eighty":45.190701,"marketCap":4821641836},{"date":"2021-10-29","current":50.169373,"twenty":32.013133,"median":39.571166,"eighty":45.28245,"marketCap":4884189150},{"date":"2021-11-05","current":43.773853,"twenty":32.013133,"median":39.651928,"eighty":45.28245,"marketCap":4934976633},{"date":"2021-11-12","current":43.137928,"twenty":32.029424,"median":39.72736,"eighty":45.28245,"marketCap":4863283742},{"date":"2021-11-19","current":43.008274,"twenty":32.198132,"median":39.802558,"eighty":45.28245,"marketCap":4848666745},{"date":"2021-11-26","current":42.662528,"twenty":32.27459,"median":39.842867,"eighty":45.28245,"marketCap":4809688086},{"date":"2021-12-03","current":42.508177,"twenty":32.348817,"median":39.911012,"eighty":45.28245,"marketCap":4792286899},{"date":"2021-12-10","current":42.891493,"twenty":32.447032,"median":39.953188,"eighty":45.28245,"marketCap":4835501148},{"date":"2021-12-17","current":45.380751,"twenty":32.521786,"median":39.996581,"eighty":45.380751,"marketCap":5116135105},{"date":"2021-12-23","current":46.352906,"twenty":32.588031,"median":40.079057,"eighty":45.406143,"marketCap":5225733953},{"date":"2021-12-31","current":48.175698,"twenty":32.64443,"median":40.10618,"eighty":45.47788,"marketCap":5431231792},{"date":"2022-01-07","current":46.703962,"twenty":32.651599,"median":40.164071,"eighty":45.565296,"marketCap":5265311314},{"date":"2022-01-14","current":46.015352,"twenty":32.70478,"median":40.208708,"eighty":45.667046,"marketCap":5187678797},{"date":"2022-01-21","current":43.267663,"twenty":32.731462,"median":40.224323,"eighty":45.667046,"marketCap":4877909831},{"date":"2022-01-28","current":43.821252,"twenty":32.743358,"median":40.249944,"eighty":45.667046,"marketCap":4940320287},{"date":"2022-02-04","current":42.666817,"twenty":32.769192,"median":40.314701,"eighty":45.667046,"marketCap":4810171655},{"date":"2022-02-11","current":42.565551,"twenty":32.769192,"median":40.347561,"eighty":45.667046,"marketCap":4798755108},{"date":"2022-02-18","current":42.943612,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4841376882},{"date":"2022-02-25","current":37.784604,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4620036905},{"date":"2022-03-04","current":38.267307,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4679058463},{"date":"2022-03-11","current":37.29027,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4559593141},{"date":"2022-03-18","current":37.24956,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4554615419},{"date":"2022-03-25","current":38.110019,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4659826391},{"date":"2022-04-01","current":39.298046,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4805089927},{"date":"2022-04-08","current":39.763938,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4862056020},{"date":"2022-04-14","current":40.742313,"twenty":32.769192,"median":40.404479,"eighty":45.667046,"marketCap":4981684815},{"date":"2022-04-22","current":42.01187,"twenty":32.769192,"median":40.455317,"eighty":45.667046,"marketCap":5136917418},{"date":"2022-04-29","current":39.554287,"twenty":32.79826,"median":40.479695,"eighty":45.667046,"marketCap":4836421278},{"date":"2022-05-06","current":39.499614,"twenty":32.904642,"median":40.479695,"eighty":45.667046,"marketCap":5066773466},{"date":"2022-05-13","current":39.967203,"twenty":32.996397,"median":40.479695,"eighty":45.667046,"marketCap":5126753027},{"date":"2022-05-20","current":39.90291,"twenty":33.05702,"median":40.479695,"eighty":45.667046,"marketCap":5118505838},{"date":"2022-05-27","current":40.353768,"twenty":33.088236,"median":40.495181,"eighty":45.667046,"marketCap":5176339242},{"date":"2022-06-03","current":40.599257,"twenty":33.156377,"median":40.53176,"eighty":45.667046,"marketCap":5207829139},{"date":"2022-06-10","current":41.119461,"twenty":33.227354,"median":40.613635,"eighty":45.667046,"marketCap":5274557730},{"date":"2022-06-17","current":40.213488,"twenty":33.270165,"median":40.613635,"eighty":45.667046,"marketCap":5158345016},{"date":"2022-06-24","current":43.32302,"twenty":33.260026,"median":40.659236,"eighty":45.668114,"marketCap":5557217043},{"date":"2022-07-01","current":42.978166,"twenty":33.330747,"median":40.684242,"eighty":45.668114,"marketCap":5512981235},{"date":"2022-07-08","current":42.872956,"twenty":33.466784,"median":40.715658,"eighty":45.668114,"marketCap":5499485565},{"date":"2022-07-15","current":43.708789,"twenty":33.59929,"median":40.742313,"eighty":45.668114,"marketCap":5606701167},{"date":"2022-07-22","current":44.556311,"twenty":33.59929,"median":40.778643,"eighty":45.668114,"marketCap":5715416287},{"date":"2022-07-29","current":46.520226,"twenty":33.675236,"median":40.820493,"eighty":45.678143,"marketCap":5967335462},{"date":"2022-08-05","current":43.100932,"twenty":33.675236,"median":40.862996,"eighty":45.68777,"marketCap":6116022220},{"date":"2022-08-12","current":44.318758,"twenty":33.675236,"median":40.912721,"eighty":45.68777,"marketCap":6288831702},{"date":"2022-08-19","current":44.509569,"twenty":33.675236,"median":40.969109,"eighty":45.68777,"marketCap":6315907842},{"date":"2022-08-26","current":43.241234,"twenty":33.675236,"median":41.010201,"eighty":45.68777,"marketCap":6135931147},{"date":"2022-09-02","current":41.585665,"twenty":33.675236,"median":41.060268,"eighty":45.68777,"marketCap":5901005814},{"date":"2022-09-09","current":41.956063,"twenty":33.675236,"median":41.092655,"eighty":45.68777,"marketCap":5953565380},{"date":"2022-09-16","current":40.805583,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5790312183},{"date":"2022-09-23","current":39.935707,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5666876838},{"date":"2022-09-30","current":37.927001,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5381841428},{"date":"2022-10-07","current":36.428553,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5169211706},{"date":"2022-10-14","current":35.631626,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5056127734},{"date":"2022-10-21","current":36.636203,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5198677248},{"date":"2022-10-28","current":38.359137,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5443161610},{"date":"2022-11-04","current":41.724424,"twenty":33.675236,"median":41.119461,"eighty":45.68777,"marketCap":6035896875},{"date":"2022-11-11","current":42.347632,"twenty":33.675236,"median":41.160749,"eighty":45.68777,"marketCap":6126050848},{"date":"2022-11-18","current":42.756995,"twenty":33.675236,"median":41.197005,"eighty":45.68777,"marketCap":6185269635},{"date":"2022-11-25","current":43.056379,"twenty":33.675236,"median":41.218321,"eighty":45.68777,"marketCap":6228578896},{"date":"2022-12-02","current":43.196907,"twenty":33.675236,"median":41.257018,"eighty":45.68777,"marketCap":6248907733},{"date":"2022-12-09","current":43.795676,"twenty":33.675236,"median":41.35326,"eighty":45.68777,"marketCap":6335526256},{"date":"2022-12-16","current":43.172467,"twenty":33.675236,"median":41.423201,"eighty":45.68777,"marketCap":6245372283},{"date":"2022-12-23","current":43.685698,"twenty":33.675236,"median":41.463369,"eighty":45.68777,"marketCap":6319616732},{"date":"2022-12-30","current":43.337434,"twenty":33.675236,"median":41.483593,"eighty":45.68777,"marketCap":6269236570},{"date":"2023-01-06","current":43.245786,"twenty":34.167053,"median":41.539601,"eighty":45.68777,"marketCap":6255978633},{"date":"2023-01-13","current":45.714181,"twenty":34.992765,"median":41.587683,"eighty":45.704396,"marketCap":6613059075},{"date":"2023-01-20","current":45.402576,"twenty":35.880519,"median":41.605991,"eighty":45.714503,"marketCap":6567982088},{"date":"2023-01-27","current":45.378137,"twenty":36.169649,"median":41.646285,"eighty":45.714503,"marketCap":6564446638},{"date":"2023-02-03","current":45.255939,"twenty":36.592515,"median":41.674422,"eighty":45.714503,"marketCap":6546769389},{"date":"2023-02-10","current":44.406665,"twenty":36.713651,"median":41.711398,"eighty":45.714503,"marketCap":6423912504},{"date":"2023-02-17","current":44.157808,"twenty":36.89773,"median":41.739833,"eighty":45.714503,"marketCap":6731283715},{"date":"2023-02-24","current":42.410386,"twenty":36.963658,"median":41.754028,"eighty":45.714503,"marketCap":6464912060},{"date":"2023-03-03","current":41.690165,"twenty":37.214665,"median":41.783816,"eighty":45.714503,"marketCap":6355123742},{"date":"2023-03-10","current":39.423241,"twenty":37.286636,"median":41.783816,"eighty":45.714503,"marketCap":6009560514},{"date":"2023-03-17","current":40.355986,"twenty":37.342014,"median":41.783816,"eighty":45.714503,"marketCap":6151745384},{"date":"2023-03-24","current":39.606247,"twenty":37.466803,"median":41.783816,"eighty":45.714503,"marketCap":6037457546},{"date":"2023-03-31","current":40.621801,"twenty":37.536428,"median":41.78137,"eighty":45.714342,"marketCap":6192265465},{"date":"2023-04-06","current":39.692254,"twenty":37.577737,"median":41.783816,"eighty":45.714503,"marketCap":6050568092},{"date":"2023-04-14","current":39.289647,"twenty":37.687654,"median":41.784219,"eighty":45.714663,"marketCap":5989195981},{"date":"2023-04-21","current":39.792905,"twenty":37.872566,"median":41.784621,"eighty":45.714824,"marketCap":6065911119},{"date":"2023-04-28","current":40.118543,"twenty":37.943837,"median":41.797292,"eighty":45.714985,"marketCap":6115550327},{"date":"2023-05-05","current":39.964605,"twenty":38.110019,"median":41.797292,"eighty":45.714985,"marketCap":6092084520},{"date":"2023-05-12","current":39.104119,"twenty":38.249787,"median":41.797292,"eighty":45.714985,"marketCap":6176026400},{"date":"2023-05-19","current":38.898029,"twenty":38.342909,"median":41.797292,"eighty":45.714985,"marketCap":6143476946},{"date":"2023-05-26","current":37.796919,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5969569863},{"date":"2023-06-02","current":37.832249,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5975149770},{"date":"2023-06-09","current":38.668386,"twenty":38.476762,"median":41.797292,"eighty":45.714985,"marketCap":6107207554},{"date":"2023-06-16","current":38.786152,"twenty":38.533217,"median":41.797292,"eighty":45.714985,"marketCap":6125807242},{"date":"2023-06-23","current":38.509402,"twenty":38.553397,"median":41.809962,"eighty":45.718688,"marketCap":6082097976},{"date":"2023-06-30","current":38.55062,"twenty":38.5799,"median":41.81327,"eighty":45.72239,"marketCap":6088607866},{"date":"2023-07-07","current":38.662498,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6106277570},{"date":"2023-07-14","current":38.603615,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6096977726},{"date":"2023-07-21","current":39.357316,"twenty":38.659115,"median":41.81327,"eighty":45.72239,"marketCap":6216015729},{"date":"2023-07-28","current":39.404422,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6223455604},{"date":"2023-08-04","current":38.053978,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6196443469},{"date":"2023-08-11","current":37.511193,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6108060089},{"date":"2023-08-18","current":36.166029,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5889023018},{"date":"2023-08-25","current":36.531819,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5948585730},{"date":"2023-09-01","current":36.472821,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5938978841},{"date":"2023-09-08","current":35.75304,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5821774794},{"date":"2023-09-15","current":35.446248,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5771818971},{"date":"2023-09-22","current":33.711695,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5489376431},{"date":"2023-09-29","current":32.567126,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5303002783},{"date":"2023-10-06","current":32.649724,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5316452427},{"date":"2023-10-13","current":31.806046,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5179073913},{"date":"2023-10-20","current":32.41963,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5278985560},{"date":"2023-10-27","current":33.181375,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5472604212},{"date":"2023-11-03","current":35.377246,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5834769220},{"date":"2023-11-10","current":34.598655,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5706356142},{"date":"2023-11-17","current":35.425908,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5842795038},{"date":"2023-11-24","current":35.170433,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5800659496},{"date":"2023-12-01","current":36.015934,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5940108073},{"date":"2023-12-08","current":36.873602,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6081563104},{"date":"2023-12-15","current":37.7556,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6227031044},{"date":"2023-12-22","current":37.968496,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6262143995},{"date":"2023-12-29","current":38.607184,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":6367482847},{"date":"2024-01-05","current":38.296964,"twenty":38.756995,"median":41.871582,"eighty":45.73451,"marketCap":6316318262},{"date":"2024-01-12","current":38.090151,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":6282208538},{"date":"2024-01-19","current":36.989174,"twenty":38.764196,"median":41.872103,"eighty":45.735522,"marketCap":6100624420},{"date":"2024-01-26","current":36.295741,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":5986256523},{"date":"2024-02-02","current":37.232484,"twenty":38.697827,"median":41.871582,"eighty":45.73451,"marketCap":6140753507},{"date":"2024-02-09","current":35.261674,"twenty":38.661168,"median":41.871582,"eighty":45.73451,"marketCap":5815707904},{"date":"2024-02-16","current":33.847315,"twenty":38.629468,"median":41.871582,"eighty":45.73451,"marketCap":5752655855},{"date":"2024-02-23","current":33.670228,"twenty":38.597685,"median":41.871582,"eighty":45.73451,"marketCap":5722558249},{"date":"2024-03-01","current":32.436519,"twenty":38.556509,"median":41.871061,"eighty":45.733498,"marketCap":5512878257},{"date":"2024-03-08","current":33.758772,"twenty":38.535146,"median":41.871061,"eighty":45.733498,"marketCap":5737607052},{"date":"2024-03-15","current":32.6018,"twenty":38.489062,"median":41.871061,"eighty":45.733498,"marketCap":5540969356},{"date":"2024-03-22","current":33.262927,"twenty":38.456408,"median":41.871061,"eighty":45.733498,"marketCap":5653333754},{"date":"2024-03-28","current":33.457723,"twenty":38.385748,"median":41.784621,"eighty":45.733498,"marketCap":5686441121},{"date":"2024-04-05","current":33.192092,"twenty":38.338315,"median":41.766476,"eighty":45.73451,"marketCap":5641294711},{"date":"2024-04-12","current":33.499043,"twenty":38.271415,"median":41.746116,"eighty":45.73451,"marketCap":5693463896},{"date":"2024-04-19","current":32.99201,"twenty":38.226469,"median":41.73308,"eighty":45.73451,"marketCap":5607289064},{"date":"2024-04-26","current":33.647761,"twenty":38.150217,"median":41.720309,"eighty":45.733498,"marketCap":5827926731},{"date":"2024-05-03","current":33.618779,"twenty":38.090151,"median":41.711398,"eighty":45.733498,"marketCap":5822906984},{"date":"2024-05-10","current":34.482434,"twenty":38.029323,"median":41.69585,"eighty":45.733498,"marketCap":5972495456},{"date":"2024-05-17","current":34.986715,"twenty":37.950247,"median":41.66791,"eighty":45.733498,"marketCap":6059839061},{"date":"2024-05-24","current":34.198413,"twenty":37.871294,"median":41.619337,"eighty":45.733498,"marketCap":5923301932},{"date":"2024-05-31","current":34.928752,"twenty":37.820473,"median":41.602226,"eighty":45.733498,"marketCap":6049799566},{"date":"2024-06-07","current":35.908334,"twenty":37.7418,"median":41.585665,"eighty":45.733498,"marketCap":6219467028},{"date":"2024-06-14","current":35.311311,"twenty":37.642264,"median":41.478607,"eighty":45.73451,"marketCap":6116060232},{"date":"2024-06-21","current":35.485201,"twenty":37.563829,"median":41.447441,"eighty":45.735522,"marketCap":6146178716},{"date":"2024-06-28","current":35.734443,"twenty":37.537078,"median":41.447441,"eighty":45.738558,"marketCap":6189348544},{"date":"2024-07-05","current":35.879352,"twenty":37.482188,"median":41.447441,"eighty":45.738558,"marketCap":6214447281},{"date":"2024-07-12","current":36.957471,"twenty":37.418215,"median":41.439295,"eighty":45.738558,"marketCap":6401181884},{"date":"2024-07-15","current":37.189325,"twenty":37.412399,"median":41.439295,"eighty":45.738558,"marketCap":6441339863},{"date":"2024-08-02","current":37.993919,"twenty":37.339153,"median":41.40142,"eighty":45.707657,"marketCap":7107142493},{"date":"2024-08-09","current":38.417922,"twenty":37.339153,"median":41.351038,"eighty":45.669183,"marketCap":7186456557},{"date":"2024-08-16","current":38.455492,"twenty":37.339153,"median":41.248609,"eighty":45.587895,"marketCap":7193484385},{"date":"2024-08-23","current":38.879496,"twenty":37.339153,"median":41.197005,"eighty":45.51208,"marketCap":7272798449},{"date":"2024-08-30","current":39.104915,"twenty":37.339153,"median":41.152223,"eighty":45.432939,"marketCap":7314965420},{"date":"2024-09-06","current":40.19981,"twenty":37.339153,"median":41.109476,"eighty":45.406991,"marketCap":7519776420},{"date":"2024-09-13","current":40.725789,"twenty":37.339153,"median":41.060268,"eighty":45.379705,"marketCap":7618166018},{"date":"2024-09-20","current":39.786541,"twenty":37.339153,"median":41.020981,"eighty":45.296882,"marketCap":7442470307},{"date":"2024-09-27","current":39.931453,"twenty":37.339153,"median":40.992653,"eighty":45.271719,"marketCap":7469577645},{"date":"2024-10-04","current":40.355457,"twenty":37.339153,"median":40.937316,"eighty":45.211095,"marketCap":7548891709},{"date":"2024-10-11","current":39.3196,"twenty":37.339153,"median":40.894276,"eighty":45.159517,"marketCap":7355124439},{"date":"2024-10-18","current":40.731156,"twenty":37.339153,"median":40.838938,"eighty":45.089028,"marketCap":7619169993},{"date":"2024-10-25","current":42.532506,"twenty":37.339153,"median":40.820493,"eighty":45.046981,"marketCap":8077475775},{"date":"2024-10-31","current":40.816625,"twenty":37.339153,"median":40.816625,"eighty":44.988744,"marketCap":7751607762},{"date":"2024-11-08","current":40.076878,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7611120201},{"date":"2024-11-15","current":41.115788,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7808422584},{"date":"2024-11-22","current":41.948003,"twenty":37.338438,"median":40.773001,"eighty":44.914929,"marketCap":7966471090},{"date":"2024-11-29","current":41.773945,"twenty":37.338438,"median":40.773001,"eighty":44.914324,"marketCap":7933415193},{"date":"2024-12-06","current":40.849261,"twenty":37.338438,"median":40.770318,"eighty":44.892115,"marketCap":7757805742},{"date":"2024-12-13","current":40.055121,"twenty":37.338438,"median":40.736734,"eighty":44.892115,"marketCap":7606988214},{"date":"2024-12-20","current":37.770608,"twenty":37.338438,"median":40.680888,"eighty":44.892115,"marketCap":7173129570},{"date":"2024-12-27","current":38.515795,"twenty":37.338438,"median":40.640959,"eighty":44.892115,"marketCap":7314650128},{"date":"2025-01-03","current":37.933788,"twenty":37.338438,"median":40.614232,"eighty":44.892115,"marketCap":7204119473},{"date":"2025-01-10","current":37.906591,"twenty":37.337724,"median":40.580698,"eighty":44.89414,"marketCap":7198954490},{"date":"2025-01-17","current":39.244663,"twenty":37.333873,"median":40.538993,"eighty":44.89414,"marketCap":7453071695},{"date":"2025-01-24","current":38.87479,"twenty":37.333873,"median":40.501145,"eighty":44.89414,"marketCap":7382827915},{"date":"2025-01-31","current":39.761398,"twenty":37.333873,"median":40.465332,"eighty":44.84311,"marketCap":7551206388},{"date":"2025-02-07","current":39.74508,"twenty":37.333873,"median":40.424995,"eighty":44.718497,"marketCap":7548107398},{"date":"2025-02-14","current":40.634976,"twenty":37.333873,"median":40.403761,"eighty":44.67404,"marketCap":7688015540},{"date":"2025-02-21","current":40.363435,"twenty":37.333873,"median":40.374953,"eighty":44.653159,"marketCap":7636640801},{"date":"2025-02-28","current":41.687197,"twenty":37.333873,"median":40.374953,"eighty":44.559412,"marketCap":7887092651},{"date":"2025-03-07","current":42.394335,"twenty":37.33306,"median":40.37194,"eighty":44.562299,"marketCap":8020881032},{"date":"2025-03-14","current":42.767704,"twenty":37.33306,"median":40.383179,"eighty":44.562299,"marketCap":8091521298},{"date":"2025-03-21","current":43.141073,"twenty":37.417052,"median":40.40791,"eighty":44.562299,"marketCap":8162161563},{"date":"2025-03-28","current":42.993988,"twenty":37.479862,"median":40.452151,"eighty":44.562299,"marketCap":8134333580},{"date":"2025-04-04","current":43.440899,"twenty":37.536428,"median":40.487288,"eighty":44.562299,"marketCap":8218887836},{"date":"2025-04-11","current":41.268572,"twenty":37.537078,"median":40.501145,"eighty":44.559412,"marketCap":7807889929},{"date":"2025-04-17","current":44.145605,"twenty":37.540692,"median":40.519212,"eighty":44.559412,"marketCap":8352216066},{"date":"2025-04-25","current":43.782817,"twenty":37.571542,"median":40.572736,"eighty":44.653759,"marketCap":8377141546},{"date":"2025-05-02","current":45.953462,"twenty":37.571542,"median":40.583839,"eighty":44.677947,"marketCap":8792459672},{"date":"2025-05-09","current":43.031008,"twenty":37.571542,"median":40.598117,"eighty":44.677947,"marketCap":8233294969},{"date":"2025-05-16","current":42.422675,"twenty":37.571542,"median":40.624906,"eighty":44.677947,"marketCap":8116900028},{"date":"2025-05-22","current":43.002313,"twenty":37.571542,"median":40.653059,"eighty":44.677947,"marketCap":8227804641}],"updateTime":1748005519968}}}